International pharmaceutical companies remain crucial in shaping Russia's healthcare system. Their influence extends far beyond merely providing medications. Today, they focus on technology transfer, scientific research, doctor education, and accelerating patient access to innovative treatments. This was discussed in an interview with Larisa Matveeva, Executive Director of the Association of International Pharmaceutical Manufacturers (AIPM).
She emphasized that a critical focus remains on technological collaboration with Russian healthcare. International firms share production technologies, establish local drug manufacturing facilities in Russia, and engage in ongoing joint research initiatives.
"The terms 'cooperation,' 'partnership,' and 'joint work' are frequently used today. International pharmaceutical companies excel in these areas, thanks to their extensive global experience and accumulated expertise," noted Larisa Matveeva.
She emphasized that it remains an important task to create a so-called seamless patient journey, from timely diagnosis to access to modern therapies. Diagnostic programs and mechanisms for early access to innovative medicines play a crucial role in this effort.
According to Larisa Matveeva, international companies are currently implementing over 50 diagnostic programs in Russia, with a total value of over 2 billion rubles. Of these, 19 programs focus on the most socially significant diseases, including cancer, diabetes, and cardiovascular diseases.
According to Larisa Matveeva, international companies are currently implementing over 50 diagnostic programs in Russia, with a total value of over 2 billion rubles. Of these, 19 programs focus on the most socially significant diseases, including cancer, diabetes, and cardiovascular diseases.
Early diagnosis can save lives and reduce strain on the healthcare system. Detecting diseases promptly allows for quicker treatment
Another important area, according to the expert, is humanitarian early access programs, which allow patients to receive innovative therapies before the drug is officially registered in the country.
According to the association, more than 20,000 patients have received treatment through these programs in recent years, including over 8,000 patients with cancer.
International pharmaceutical companies also play a significant role in medical education. According to Larisa Matveeva, such initiatives help to reduce the gap in access to medical care between major federal centers and regions, and also ensure a constant exchange of scientific knowledge.
According to the association, more than 20,000 patients have received treatment through these programs in recent years, including over 8,000 patients with cancer.
International pharmaceutical companies also play a significant role in medical education. According to Larisa Matveeva, such initiatives help to reduce the gap in access to medical care between major federal centers and regions, and also ensure a constant exchange of scientific knowledge.
Over the past year, more than 6,000 educational events for doctors have been held. More than 35,000 specialists from over 6,000 medical institutions in 80 regions of the country, from Kaliningrad to Vladivostok, have participated in these events
Despite the geopolitical situation, international manufacturers remain present in the Russian market and continue to introduce new drugs. According to Larisa Matveeva, more than 100 innovative drugs from international companies have been registered in Russia over the past five years. Approximately the same number of registrations are expected in the next five years.
New drugs continue to be approved, especially innovative ones. The registration process mirrors global trends in the pharmaceutical industry
According to her, the industry is gradually moving from traditional chemical drugs to high-tech solutions, including biotechnological and targeted drugs. This opens up new opportunities for treating complex diseases, but it also requires further improvement of regulation.
Larisa Matveeva believes that it is important to maintain conditions for patients to have quick access to innovations at all stages of the drug's life cycle, from clinical research and registration to procurement and inclusion in the state guarantee system.
She also emphasized the importance of protecting intellectual property. According to her, it is clear and predictable rules that allow pharmaceutical companies to continue investing in research and bringing new drugs to the market.
Larisa Matveeva believes that it is important to maintain conditions for patients to have quick access to innovations at all stages of the drug's life cycle, from clinical research and registration to procurement and inclusion in the state guarantee system.
She also emphasized the importance of protecting intellectual property. According to her, it is clear and predictable rules that allow pharmaceutical companies to continue investing in research and bringing new drugs to the market.
Striking a balance of interests among all system participants is crucial. Clear and transparent rules benefit both government and industry, but most importantly, patients do
According to her, the industry continues to engage in constant dialogue with regulators on improving legislation and developing support mechanisms for innovative medicine. The main goal of this work is to provide Russian patients with the fastest possible access to modern diagnostic and treatment methods.
Source: RG.RU